Clinical Genomics growth
July 16, 2015
Clinical Genomics, the
Australian biotechnology company
which manufactures the faecal
immunochemical test (FIT) for
bowel cancer, is expanding
internationally, with distribution
deals signed in New Zealand and
the Philippines.
The company’s InSure FIT product,
which is FDA-approved, will pioneer
faecal immunochemical testing in
the Philippines where colorectal
cancer is the fourth highest cause
of cancer-related death.
“There is a huge opportunity in
that market given the effectiveness
of our technology,” said Clinical
Genomics vice-president AsiaPacific,
Warren Bingham.
Clinical Genomics has also
renewed an exclusive distribution
deal with NZ-based Green Cross
Health Limited, which represents about 300 community pharmacies
trading under the Life Pharmacy
and Unichem brands.
These latest deals follow an
exclusive distribution agreement
for the technology in China,
where BioChain Group is working
with Clinical Genomics to secure
approval from the Chinese Food
and Drug Administration.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 15
